• Return to HOME


  • Home
  • Services
    • Clinical & Medical Consulting
    • Business Development
    • Pharmaceutical
    • Regulatory Affairs
    • Legal Consulting
  • Our Team
    • Michael Epstein, MD, FACG, AGAF
  • News
  • Blog
  • Contact


Pooled Safety and Tolerability Data From 4 Phase 3, Randomized, Active-Controlled Studies of a Low-Volume Sodium Picosulfate/Magnesium Citrate Bowel Preparation for Colonoscopy

July 11, 2017
by Epstein Associates
Comments are off

Bertiger, Gerald2 ; Epstein, Michael3 ; Lu, Liang4 ; Kitamura, Mikiya5 ; Bradesi, Sylvie1 ; Seifu, Yodit1 ; Brogadir, Stuart1

INSTITUTIONS (ALL):

  1. Ferring Pharmaceuticals Inc., Parsippany, NJ, United States.
  2. Hillmont G.I., Flourtown, PA, United States.
  3. Digestive Disorders Associates, Annapolis, MD, United States.
  4. Ferring International Pharma-Science Centre (China) Co. Ltd., Beijing, China.
  5. Ferring Pharmaceuticals Co. Ltd., Tokyo, Japan.

 

Pristine cleansing and a positive bowel preparation experience are critical to promote patient adherence to screening recommendations and a successful colonoscopy. Low-volume preparations may improve patient experience and potentially improve adherence. We conducted a pooled analysis of clinical trial safety and tolerability data for sodium picosulfate and magnesium citrate (P/MC), a nonphosphate, low-volume, dual-action bowel preparation.

Methods: We analyzed pooled data from 4 large, phase 3, randomized, multicenter, assessor-blinded studies which evaluated the safety and tolerability of P/MC (split-dose or day-before dose). All trials monitored adverse event (AE) frequency, type, severity, serious AEs (SAEs), AEs leading to discontinuation, and adverse drug reactions (AEs judged possibly/probably related to study drug by investigators). To evaluate tolerability, the majority of patients were asked a version of 3 questions: 1) Were you able to consume the entire preparation as instructed? 2) Would you ask your doctor for this preparation again if you need another colonoscopy in the future? 3) Would you refuse the same preparation again if it were to be prescribed to you in the future? Results: A total of 1171 patients across the 4 studies were randomized to the P/MC group (split-dose, n=663; daybefore dose, n=508) and were included in the analysis. Mean (SD) age was 51.9 (12.7) years, with 15.9% patients aged 65 to 83 years; 56.3% were female; 46.0%, white; and 5.0%, African American. Adverse drug reactions occurred in 146 patients (12.5%). Reported AEs commonly associated with bowel preparation included nausea, headache, and vomiting, which occurred in 5.3%, 2.2%, and 1.5% of P/MC patients, respectively. Most AEs were mild to moderate in severity, with 9 patients (0.8%) experiencing a severe AE. No patients reported an AE leading to discontinuation. Among respondents that received P/MC, 99.4% reported that they consumed the entire preparation as instructed, 92.8% reported that they would ask their doctor for the same preparation in a future colonoscopy, and 3.4% reported that they would refuse this preparation if prescribed again. Results were similar across P/MC dose regimens for the first 2 questions. With regards to the third question, 2.1% of patients given split-dose P/MC said they would refuse repeat prescription vs 4.7% of patients given day-before P/MC.

Conclusions: In this large, pooled sample, P/MC was well tolerated across dosing regimens among adults undergoing colonoscopy with a relatively low incidence of AEs

Social Share
  • google-share

Key Services

  • Clinical & Medical Consulting
  • Business Development
  • Pharmaceutical
  • Regulatory Affairs
  • Legal Consulting

News & Announcements

Achieving successful bowel preparation with evening/morning split-dosing regimens of NER1006 versus trisulfate: post hoc analysis of a Phase 3 trial
Jul 25, 2017
Novel 1L Polyethylene Glycol (PEG)-Based Bowel Preparation NER1006 Achieves High Quality Bowel Cleansing with a Lower Volume than Standard 2L PEG + Ascorbate and Under 3L Total Fluid Volume Intake
Jul 25, 2017
Bowel preparation quality of NER1006 versus oral trisulfate solution as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial
Jul 25, 2017

410-224-4887 x453

Epstein Associates, LLC
621 Ridgely Avenue, Suite 204
Annapolis, MD 21401

  • Home
  • Services
  • Our Team
  • News
  • Blog
  • Contact

© Copyright 2015, Epstein Associates, LLC
Website Design by Calvert Design Group, Inc.